How E. coli Acid Response Mechanisms Breach Colonization Resistance in the Vagina
大肠杆菌酸反应机制如何突破阴道定植抗性
基本信息
- 批准号:10657442
- 负责人:
- 金额:$ 55.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcidsBacteriaBladderCervix UteriDataDeaminaseDeaminationEnvironmentEpithelial CellsEscherichia coliEscherichia coli InfectionsGenitourinary systemGnotobioticGravidHornsHumanIn VitroIndividualInfectionInfection preventionIntestinesKnowledgeLactic acidLactobacillusLactobacillus delbrueckiiLife StyleLocationMapsMeasuresModelingMusNutrient availabilityOutputPathogenesisPathway interactionsPredispositionPregnancyPreventionProbioticsProductionProphylactic treatmentReactionRegulationReportingResistanceRoleSamplingSerineSignal TransductionSystemTestingTimeToxinUrinary tractUrinary tract infectionUropathogenic E. coliUterusVaginaWomanacid stresscolonization resistancecombatenteric infectionfitnessin vitro Modelin vivoin vivo evaluationmembermicrobiotamutantnovelpathogenpathogenic Escherichia colipathogenic bacteriapreventprophylacticprotective effectresistance mechanismresponsestillbirthtissue cultureurogenital tractvaginal microbiota
项目摘要
SUMMARY
This proposal will test the over-arching hypothesis that extra-intestinal pathogenic Escherichia coli
(ExPEC) overcomes inhibition by urogenital Lactobacilli via sequential activation of inter-connected acid
resistance (AR) mechanisms. We further postulate that transient internalization of ExPEC into vaginal epithelial
cells increases fitness by enhancing induction of acid resistance and other mechanisms of persistence that
enable bacteria to gain access and survive in otherwise harsh host environments. The hypothesis to be tested
has been formulated based on the following strong preliminary data: (1) We discovered a novel AR mechanism
in ExPEC that is controlled via a non-canonical signaling system, BtsS-YpdB and it uses L-serine deamination
to neutralize bacterial cytosolic pH. We call this new AR mechanism, AR6. (2) BtsS-YpdB signaling is induced
during infection and in response to several Lactobacillus species. (3) Deletion of btsS-ypdB significantly
decreases ExPEC acid tolerance and vaginal colonization. (4) Strains lacking L-serine deaminases, or BtsS-
YpdB differentially react to the inhibitory actions of representative urogenital L. gasseri and L. delbrueckii
isolates. (5) Deletion of btsS-ypdB alters the induction and function of the known acid-sensing system EvgSA
that controls the most prominent, known AR mechanism, AR2. We will test these hypotheses using the most
prevalent ExPEC pathotype, uropathogenic E. coli. Uropathogenic E. coli is the main cause of urinary tract
infections (UTIs), an infection that disproportionately afflicts women. Similarly, ExPEC strains are the leading
cause of infection-related stillbirths. Despite the dominant paradigm that the low pH of vagina is protective against
pathogens, we and others have shown that colonization of the vagina by ExPEC can serve as a nidus for infection
of the urinary tract, the cervix, uterine horns and the gravid uterus. Vaginal colonization is therefore a key step
in pathogenesis. While several acid resistance (AR) mechanisms have been identified that are active in the gut,
the relative contribution of each AR mechanism during ExPEC infection remains undefined. With our aims, we
will: Interrogate the significance of transient bacterial expansion in the host as a priming niche for the
amplification of acid resistance and other persistence mechanisms (Aim 1). We will evaluate the individual and
combined contributions of AR mechanisms to the colonization potential of ExPEC in the vagina, bladder and gut
and will elucidate the connection of the novel AR6 pathway we discovered to the induction and function of AR2
(Aim 2). Finally, building on exciting preliminary data we will investigate the potential of urogenital Lactobacilli
strains in their ability to override ExPEC acid resistance, aiming to identify effective probiotic strategies to prevent
ExPEC reservoir formation in the vagina (Aim 3). Completion these aims will uncover how ExPEC leverage
their multiple AR systems to transit the host and evade elimination and will inform our efforts towards
developing effective probiotic strategies to prevent, vaginal colonization and combat genitourinary tract
infections.
概括
该提案将检验以下一个超大的假设,即肠外致病性大肠杆菌
(Expec)通过连接酸的顺序激活泌尿生殖器乳酸杆菌的抑制作用
电阻(AR)机制。我们进一步假设将excec的瞬时内在化成阴道上皮
细胞通过增强抗酸的抗性和其他持久机制来提高适应性
使细菌能够进入并在其他苛刻的宿主环境中生存。要检验的假设
已经根据以下强初步数据制定了:(1)我们发现了一种新型的AR机制
在通过非典型信号系统控制的Expec中,BTSS-ippDB,并使用L serine Deamination
中和细菌胞质pH。我们称这种新的AR机制AR6。 (2)诱导BTSS-ippDB信号传导
在感染期间和对几种乳杆菌的响应。 (3)删除BTSS-ippDB
降低了酸耐受性和阴道定植。 (4)缺乏L丝氨酸脱氨酶或BTSS-的菌株
YPDB对代表性的泌尿生殖器L. gasseri和L. delbrueckii的抑制作用差异反应
分离物。 (5)删除BTSS-ippDB改变了已知的酸敏感系统EVGSA的诱导和功能
控制最突出的,已知的AR机制AR2。我们将使用最多的假设来检验这些假设
普遍的Expec病理类型,尿路发育大肠杆菌。肝病大肠杆菌是尿路的主要原因
感染(UTI),这种感染不成比例地困扰着女性。同样,expec菌株是领先的
与感染相关的死亡原因。尽管具有主要范式,即阴道的低pH值保护
病原体,我们和其他人已经表明,Expec对阴道的定殖可以作为感染的Nidus
尿路,子宫颈,子宫角和妊娠子宫。因此,阴道定植是关键步骤
在发病机理中。虽然已经确定了在肠道中活跃的几种抗酸性(AR)机制
Excec感染期间每种AR机制的相对贡献仍然不确定。以我们的目标,我们
意愿:审问宿主中短暂细菌膨胀的重要性
酸耐药性和其他持久性机制的扩增(AIM 1)。我们将评估个人,
AR机制对在阴道,膀胱和肠道中的定殖潜力的合并贡献
并将阐明我们发现的新型AR6途径与AR2的诱导和功能的连接
(目标2)。最后,以令人兴奋的初步数据为基础,我们将研究泌尿生殖的潜力
其覆盖过度抗酸性抗性的能力的压力,旨在识别有效的益生菌策略以防止
expec储层在阴道中形成(AIM 3)。完成这些目标将揭示如何指示杠杆
他们的多个AR系统可以过境主机和逃避淘汰,并将为我们的努力提供努力
制定有效的益生菌策略来预防,阴道定植和战斗
感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maria Hadjifrangiskou其他文献
Maria Hadjifrangiskou的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maria Hadjifrangiskou', 18)}}的其他基金
Targeting cytochrome bd as an anti-biofilm strategy
靶向细胞色素 bd 作为抗生物膜策略
- 批准号:
10642243 - 财政年份:2023
- 资助金额:
$ 55.51万 - 项目类别:
Two-component system interactions as uropathogenic Escherichia coli drug targets
作为尿路致病性大肠杆菌药物靶标的两组分系统相互作用
- 批准号:
8816807 - 财政年份:2014
- 资助金额:
$ 55.51万 - 项目类别:
Two-component system interactions as uropathogenic Escherichia coli drug targets
作为尿路致病性大肠杆菌药物靶标的两组分系统相互作用
- 批准号:
9252820 - 财政年份:2014
- 资助金额:
$ 55.51万 - 项目类别:
Two-component system interactions as uropathogenic Escherichia coli drug targets
作为尿路致病性大肠杆菌药物靶标的两组分系统相互作用
- 批准号:
9172228 - 财政年份:2014
- 资助金额:
$ 55.51万 - 项目类别:
Administration and Regulation of Activities associated with The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical Discovery
与范德比尔特泌尿感染存储库(个性化临床发现资源)相关的活动的管理和监管
- 批准号:
10022301 - 财政年份:
- 资助金额:
$ 55.51万 - 项目类别:
The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical Discovery
范德比尔特泌尿感染存储库,个性化临床发现的资源
- 批准号:
9913352 - 财政年份:
- 资助金额:
$ 55.51万 - 项目类别:
The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical Discovery
范德比尔特泌尿感染存储库,个性化临床发现的资源
- 批准号:
10022306 - 财政年份:
- 资助金额:
$ 55.51万 - 项目类别:
Administration and Regulation of Activities associated with The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical Discovery
范德比尔特泌尿感染信息库(个性化临床发现资源)相关活动的管理和监管
- 批准号:
9913351 - 财政年份:
- 资助金额:
$ 55.51万 - 项目类别:
相似国自然基金
膀胱上皮细胞来源外泌体microRNA调控骨髓来源抑制性细胞(MDSC)影响膀胱细菌感染结局的机制研究
- 批准号:81900637
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
基于FimH\整合素α3、β1\FAK介导的UPEC侵袭膀胱上皮细胞途径研究尿感方抗UTI的作用机制
- 批准号:81874362
- 批准年份:2018
- 资助金额:59.0 万元
- 项目类别:面上项目
基于细菌生物膜反应器构建大肠埃希菌生物膜感染力学生物学机制之研究
- 批准号:31600759
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
胎球蛋白A在间质性膀胱炎发病机制中的作用研究
- 批准号:81471444
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
纳米细菌在间质性膀胱炎发病机制中作用的实验研究
- 批准号:81000241
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Harnessing polymicrobial interactions in the catheterized urinary tract to identify novel inhibitors of Proteus mirabilis urease activity
利用插管尿路中的多种微生物相互作用来鉴定奇异变形杆菌尿素酶活性的新型抑制剂
- 批准号:
10678389 - 财政年份:2023
- 资助金额:
$ 55.51万 - 项目类别:
Durable fluid-like surface for sustainable biofilm inhibition
耐用的流体状表面可实现可持续的生物膜抑制
- 批准号:
10646770 - 财政年份:2023
- 资助金额:
$ 55.51万 - 项目类别:
Mucosal Immune Defense Mechanisms of the Urinary Bladder
膀胱粘膜免疫防御机制
- 批准号:
10587639 - 财政年份:2023
- 资助金额:
$ 55.51万 - 项目类别:
The roles of fosfomycin resistant subpopulations of Escherichia coli in urinary tract infection.
大肠杆菌磷霉素耐药亚群在尿路感染中的作用。
- 批准号:
10603417 - 财政年份:2023
- 资助金额:
$ 55.51万 - 项目类别:
Identification of bacterial small molecule inhibitors of Proteus mirabilis urease activity
奇异变形杆菌脲酶活性细菌小分子抑制剂的鉴定
- 批准号:
10348347 - 财政年份:2022
- 资助金额:
$ 55.51万 - 项目类别: